Genmab — August 2017
-
-
En fin artikel som kort beskriver virksomheden, men jeg syntes der mangler noget om konkurrenter og markedet generelt. Jeg er ikke helt vild med at man fokuserer alene på det positive.
-
Mens vi venter på nogle bedre recept/salgs-tal for dara i 2. linje: "Therefore, daratumumab
represents a landmark advance in the treatment of MM and daratumumab-based combinations will
certainly be the first choice in relapsed MM in the near future." http://www.bloodjournal.org/content/bloodjournal/early/2017/07/05/blood-2017-03-726703.full.pdf?sso-checked=true -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind